Advanced Viral Research Files an Amendment to its Existing IND to Include Topical and Intralesional Therapy
14th Nov 2006, 16:38 GMT
Advanced Viral Research a bio-pharmaceutical company, filed an amendment with the FDA to its existing IND to expand the use of its product, AVR118 to include topical and intralesional therapy.
Advanced Viral Research Files an Amendment to its Existing IND to Include Topical and Intralesional Therapy related news:
- Adding radiation therapy for treatment of advanced prostate cancer may offer benefit — EurekAlert! - Medicine and Health
- Volume 194, number 12: A Randomized, Partially Blinded Phase 2 Trial of Antiretroviral Therapy, HIV-Specific Immunizations, and Interleukin-2 Cycles to Promote Efficient Control of Viral Replication (ACTG A5024) — J Infect Dis Latest Issue
- ART Advanced Research Technologies Announces 2006 Third Quarter Financial Results — ArriveNet : Health
- ART Advanced Research Technologies Inc.: ART Advanced Research Technologies Announces 2006 Third Quarter Financial Results — Market Wire - Earnings Reports
- Chicago City Council Member Proposes Budget Amendment To Increase HIV Prevention Funding By $1.7M — Health News from Medical News Today
- WelChol and Ezetimibe Combination Therapy Provides Significant LDL-C Reductions — Cardiology News from StratCenter.com
- Testosterone replacement therapy appears safe for prostate — EurekAlert! - Medicine and Health
- Kahle v. Gonzales — Lessig Blog
- First Amendment Congress this week — NewsOk.com - NewsOK News
- Mo. Catholics Back Stem Cell Research — The Christian Post RSS Feed
Latest news from Bio-Technology News from StratCenter.com:
- IBT Labs Invests $2 mln to Expand Pharmaceutical Services Division
- Mercury Computer Systems Collaborates with Boston Univ to Deliver Biotech Application on the Cell BE Processor
- Nabi Biopharmaceuticals and 3rd Point Reach Agreement
- Epratuzumab and Rituximab Have Different Modes of Action
- avVaa World Health Care Products Signs New Spokesman
- China Biopharma Delivers 1.5 mln Doses of Flu Vaccine in China
- Osteologix Appoints Jeremy Curnock Cook to its Board
- Favrille Announces Interim Analysis of Secondary Endpoint from Pivotal Phase 3 Clinical Trial of FavId Following Rituxan in Follicular B-Cell Non-Hodgkin's Lymphoma
- Medarex to Receive Milestone Payment from Amgen
- Arqule Early Cancer Study Shows Progress